
1. aids action. 1995 sep-nov;(30):2-3.

slow progress hiv.

alcorn k.

pip: treatment people hiv attempts prevent hiv reproducing,
boost immune system, cure opportunistic infections. chemical structure
of anti-viral drugs similar dna. since hiv bonds drugs
rather dna, cannot replicate itself. widely used anti-viral drug
is zidovudine azt (brand name, retrovir), help hiv infected
persons still healthy. recent trial shows combination of
anti-viral drugs likely delay opportunistic infections death 
azt alone. pregnant women use azt delivery 
newborns receive azt therapy, likelihood hiv transmission newborn
is reduced 66%. follow-up studies needed, however, since azt is
toxic. disadvantages anti-viral drugs include resistance, toxicity, side
effects (e.g., nausea anemia), particularly severe high doses,
and accessibility regular expensive monitoring tests. protease inhibitors 
are early stages development. deactivate hiv enzyme which
allows hiv attach white blood cells. imuthiol (dtc) aims increase the
number white blood cells body fight hiv longer, appears that
it benefit may even facilitate development opportunistic
infections. interleuken 2 may increase number cd4 cells. alternative
approaches strengthening immune system lifestyle changes, improved
diet, reduced stress, chinese medicine acupuncture, herbal medicines, and
relaxation exercises. hiv/aids therapies expensive often induce side
effects. many hiv positive people developed countries opting 
treatments, even though access them. prevention treatment of
opportunistic infection remain best strategies hiv-infected persons.

pmid: 12290561  [indexed medline]

